PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1299130 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.0%
TTM net income YoY75.0%
TTM EPS YoY81.2%
Revenue 3-yr CAGR2.9%
Net income 3-yr CAGR—
Margins
Gross margin36.4%
Operating margin-83.5%
Net margin-82.5%
FCF margin-77.5%
EBITDA margin-77.4%
Returns
ROE-929.3%
ROA-16.7%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets104.4%
Debt / equity—
Current ratio4.92x
Interest coverage-18.15x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $160.00M | $154.01M | $200.52M | $128.30M | $130.51M |
| Cost of revenue | $114.22M | $116.73M | $147.74M | $79.27M | $71.65M |
| Gross profit | $45.78M | $37.28M | $52.78M | $49.03M | $58.86M |
| R&D expense | $97.31M | $134.92M | $187.17M | $193.00M | $112.90M |
| SG&A expense | $141.49M | $175.02M | $169.82M | $160.85M | $124.12M |
| Operating income | -$553.86M | -$474.31M | -$334.47M | -$307.20M | -$210.44M |
| Interest expense | $6.95M | $13.41M | $14.34M | $14.69M | $12.53M |
| Pretax income | -$546.06M | -$309.54M | -$318.16M | -$314.25M | -$274.87M |
| Income tax | $318,000 | $316,000 | -$11.42M | $0 | -$93.65M |
| Net income | -$546.38M | -$309.85M | -$306.74M | -$314.25M | -$181.22M |
| EBITDA | -$540.87M | -$460.54M | -$323.00M | -$297.72M | -$203.24M |
| EPS (basic) | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 |
| EPS (diluted) | -1.82 | -1.59 | -1.21 | -1.40 | -0.89 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 299.96M | 288.37M | 253.63M | 224.55M | 204.14M |
| Balance sheet | |||||
| Cash & equivalents | $63.71M | $57.59M | $179.91M | $328.31M | $465.82M |
| Short-term investments | $215.80M | $334.56M | $451.50M | $447.23M | $583.67M |
| Receivables | $35.45M | $27.52M | $36.62M | $18.79M | $24.24M |
| Inventory | $49.28M | $58.76M | $56.68M | $50.38M | $24.60M |
| Current assets | $375.05M | $495.68M | $742.05M | $852.07M | $1.10B |
| PP&E, net | $24.15M | $30.50M | $36.43M | $41.58M | $32.50M |
| Goodwill | $317.76M | $317.76M | $462.26M | $409.97M | $409.97M |
| Intangibles | $15.12M | $389.57M | $456.98M | $410.25M | $410.98M |
| Total assets | $784.08M | $1.26B | $1.75B | $1.77B | $2.01B |
| Current liabilities | $72.83M | $66.30M | $95.03M | $263.33M | $71.71M |
| Short-term debt | — | $0 | $490,000 | $1.84M | $1.61M |
| Long-term debt | — | — | — | $896.68M | $896.07M |
| Total debt | — | — | — | $898.52M | $897.67M |
| Total liabilities | $778.73M | $753.85M | $1.04B | $1.20B | $1.22B |
| Shareholders' equity | $5.35M | $506.59M | $701.30M | $562.90M | $790.99M |
| Net debt | — | — | — | $570.21M | $431.86M |
| Shares outstanding | 301.96M | 294.42M | 267.74M | 226.50M | 220.98M |
| Cash flow statement | |||||
| Operating cash flow | -$111.21M | -$206.06M | -$259.17M | -$263.21M | -$111.18M |
| Capital expenditure | $2.71M | $6.19M | $8.84M | $16.75M | $5.93M |
| Free cash flow | -$113.92M | -$212.25M | -$268.02M | -$279.96M | -$117.11M |
| Investing cash flow | $115.45M | $124.00M | $4.60M | $116.08M | -$678.53M |
| Financing cash flow | $3.43M | -$42.99M | $108.89M | $9.62M | $1.17B |
| Depreciation & amortization | $12.99M | $13.77M | $11.46M | $9.48M | $7.20M |
| Stock-based compensation | $41.67M | $71.04M | $72.12M | $78.61M | $73.36M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.